- Neogen reported first-quarter fiscal 2027 revenue of $222.8 million, an increase of 6.5% compared with the prior year.
- Animal Safety revenue grew 4.2% to $59.6 million, with core growth of 8.0%.
- Food Safety revenue increased 7.4% to $163.2 million.
- The company reported a net loss of $11.9 million, while adjusted EBITDA increased to $41.6 million.
- Neogen raised its fiscal 2027 revenue guidance to $885 million–$890 million and expects to complete the pending sale of its genomics business to Zoetis by the end of December 2026, subject to regulatory approvals.
Neogen Corporation (NASDAQ: NEOG) reported revenue growth across its Food Safety and Animal Safety segments for the first quarter of fiscal year 2027, reflecting progress in the company’s operational improvement initiatives.
For the quarter ended August 31, 2026, Neogen generated $222.8 million in revenue, compared with $209.2 million during the same period last year. Core revenue, which excludes certain currency and portfolio changes, increased 8.1%.
The company reported a net loss of $11.9 million, or $0.05 per share, compared with net income of $36.3 million in the prior-year quarter. The prior-year results benefited from a noncash gain associated with the sale of Neogen’s Cleaners & Disinfectants business.
Adjusted EBITDA, a non-GAAP measure, increased to $41.6 million from $35.5 million.
Animal Safety Business Shows Growth
Neogen’s Animal Safety segment generated $59.6 million in quarterly revenue, representing 4.2% reported growth and 8.0% core growth.
The company attributed the segment’s performance to increased sales of veterinary instruments and consumables, along with growth in insect control products.
Food Safety revenue reached $163.2 million, up 7.4%, supported by demand for indicator testing, culture media and pathogen detection products.
Mike Nassif, Neogen’s president and CEO, said the company is focusing on improving commercial execution, strengthening customer service and advancing innovation initiatives.
Genomics Sale and Manufacturing Transition
Neogen also provided an update on its previously announced agreement to sell its global Genomics business to Zoetis.
The transaction remains subject to customary closing conditions and regulatory reviews, which Neogen expects to conclude by the end of December 2026.
Separately, the company said it remains on schedule to begin transitioning Petrifilm manufacturing to its Lansing, Michigan, facility in November 2026. The transition is expected to occur over multiple quarters.
Neogen also highlighted a strategic collaboration and equity investment in Hinalea Imaging Corp. to develop digital imaging technologies for food safety inspection.
Neogen Raises Fiscal 2027 Outlook
Following its first-quarter performance, Neogen increased its full-year financial guidance.
The company now expects fiscal 2027 revenue between $885 million and $890 million, compared with its previous forecast of $880 million to $885 million.
Its adjusted EBITDA outlook increased to $181 million–$183 million, up from the previous range of $180 million–$182 million.
The revised outlook reflects management’s expectations for continued growth and operational improvements, although actual results remain subject to market conditions and execution risks.
For complete financial statements, segment results, non-GAAP reconciliations and additional information, readers can access Neogen’s original earnings announcement through Neogen Investor Relations.
Information sourced from Neogen Corporation’s first-quarter fiscal 2027 financial results press release, issued October 6, 2026.
